Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults

Nakamaru, Yoshinobu; Hayashi, Yoshiharu; Davies, Martin; Heuer, Horst Jürgen; Hisanaga, Noriko; Akimoto, Kei

doi:10.1016/j.clinthera.2015.06.012

Cited by 12 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10] There were no clinically relevant drug–drug interactions when teneligliptin was coadministered with ketoconazole (a potent CYP3A4 and P-glycoprotein inhibitor), metformin, or canagliflozin in healthy volunteers. [121314]…”

Section: Review Methodsmentioning

confidence: 99%

Efficacy and safety of teneligliptin

Singh

2017

Indian J Endocr Metab

View full text Add to dashboard Cite

Section: Review Methodsmentioning

confidence: 99%

Efficacy and safety of teneligliptin

Singh

2017

Indian J Endocr Metab

View full text Add to dashboard Cite

“…These findings have resulted in eight commercially available DPP-IV inhibitors, including alogliptin (Nesina ® , Vipidia ® ; Keating, 2015;Takeda et al, 2016), anagliptin , gemigliptin (Zemiglo ® ; Kim et al, 2013;Jung et al, 2014), linagliptin (Forst and Pfutzner, 2012;Barnett, 2015), saxagliptin Anderson et al, 2016), sitagliptin (Januvia ® , Xelevia ® , Glactiv ® , Tesavel ® ; Garg et al, 2013;Plosker, 2014), teneligliptin (Nakamaru et al, 2015), and vildagliptin (Galvus ® , Novartis AG; Mikhail, 2008;Richter et al, 2008), being approved and entering into the clinic . These DPP-IV inhibitors have good oral bioavailability and a relatively long duration of action in patients with T2DM.…”

Section: Dpp-iv Inhibitor and T2dmmentioning

confidence: 95%

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Hölscher

2016

Reviews in the Neurosciences

View full text Add to dashboard Cite

AbstractIncretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared mechanisms, such as insulin dysregulation or IR, may underlie these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively investigated. Protease-resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide, and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies but also have shown first positive results in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients in clinical trials. Furthermore, the effects of other related incretin-based therapies such as GIP agonists, dipeptidyl peptidase-IV (DPP-IV) inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP, and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.

show abstract

“…No clinically relevant drug–drug interactions were observed when teneligliptin was coadministered with metformin, canagliflozin, glimepiride, or pioglitazone in healthy volunteers; therefore, no dose adjustment of teneligliptin is required when it is coadministered with these drugs. Furthermore, teneligliptin did not affect the pharmacokinetic properties of metformin, canagliflozin, glimepiride, or pioglitazone [ 31 , 38 , 39 ].…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 99%

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice

Ceriello

Nigris

Iijima

et al. 2019

Drugs

View full text Add to dashboard Cite

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t ½ of approximately 24 h and unique pharmacokinetic properties: it is metabolized by cytochrome P450 (CYP) 3A4 and flavin-containing monooxygenase 3 (FMO3), or excreted from the kidney in an unchanged form. Because of its multiple elimination pathways, dose adjustment is not needed in patients with hepatic or renal impairment, and it is considered to have a low potential for drug–drug interactions. Clinical studies and postmarketing surveillance show that teneligliptin, administered as monotherapy and/or in combination with antihyperglycemic agents, is effective and well tolerated in T2DM patients, including in elderly patients and those with renal impairment. Furthermore, teneligliptin has antioxidative properties, which induce the antioxidant cascade, as well as ·OH scavenging properties. In addition, it has shown endothelial protective effects in several non-clinical and clinical studies. From its unique profile and clinical data, teneligliptin represents a potential therapeutic option in a wide variety of patients, including elderly diabetic patients and those with renal impairment. The fixed-dose combination (FDC) tablet of teneligliptin and canagliflozin has been approved in Japan; this is the first FDC tablet of a DPP-4 inhibitor and sodium glucose co-transporter 2 inhibitor in Japan, and the third globally. The FDC tablet may also provide additional prescribing and adherence benefits.

show abstract

Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults

Cited by 12 publications

References 24 publications

Efficacy and safety of teneligliptin

Efficacy and safety of teneligliptin

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice

Contact Info

Product

Resources

About